In a historic move, the FDA has approved the first-ever blood test designed to diagnose Alzheimer's disease, marking a significant advancement in early detection and treatment options for patients.
A groundbreaking study reveals the link between 'brain fog' in long COVID patients and changes in brain chemistry, providing scientific proof for millions suffering from neurological symptoms.
The FDA has approved a groundbreaking blood test, Lumipulse, that detects amyloid plaques linked to Alzheimer’s disease, offering a safer, more accessible diagnostic tool for millions.
KJ Muldoon, born with a deadly genetic disorder, received a groundbreaking CRISPR treatment just six months after birth. His remarkable progress showcases the future of personalized medicine for rare diseases.
U.S. health officials have advised patients to pause the Ixchiq vaccine after reports of serious adverse events. Investigations are ongoing as the FDA reassesses its safety for older adults.
In a groundbreaking move, President Trump has issued an executive order aimed at ending the price discrimination faced by American consumers in the pharmaceutical market. This order seeks to ensure that Americans pay the same low prices for medications as those in other developed nations, addressing the long-standing issue of subsidizing global pharmaceutical profits.
President Trump unveils a groundbreaking executive order aimed at slashing U.S. drug prices by matching them to those in developed countries. Will this initiative reshape the pharmaceutical landscape and benefit American patients?
In a landmark move, President Trump signs an Executive Order aimed at reducing prescription drug prices for Americans, aligning them with those in other wealthy nations. This initiative seeks to curb unfair pricing practices and ensure a fair deal for U.S. patients.
President Trump signs an executive order reviving the 'most favored nation' policy to slash drug costs by linking U.S. prices to lower prices abroad. Will this finally bring relief to American patients?
In a surprising turn of events, Elizabeth Holmes' partner, Billy Evans, raises millions for an AI startup named Haemanthus, aimed at revolutionizing medical testing. As Holmes advises from prison, the venture seeks to make advanced diagnostic tools accessible to patients.
